Thrombotic thrombocytopenic purpura: diagnosis and treatment


Cite item

Full Text

About the authors

L В Filatov

A V Spirin

References

  1. Bellia M., Kontopoulou-Griva I. Thrombotic thrombocytopenic purpura: diagnosis, pathophysiology, management. Haema 2001; 4 (3): 167-180.
  2. Guidelines of the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br. J. Haematol. 2003; 120 (4): 556-573.
  3. Lammle В., Furlan M. New insights into the pathogenesis of thrombotic thrombocytopenic purpura. Hematology 1999. 243-248.
  4. McCrae K. R., Bussel J. В., Mannucci P. M. et al. Platelets: an update on diagnosis and management of thrombocytopenic disorders. Hematology 2001. 282-305.
  5. George J. N., Sadler J. £., Lammle B. Platelets: thrombotic thrombocytopenic purpura. Hematology 2002. 315-334.
  6. Rock G. A., Shumak К. Н., Buskard N. A. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 1991; 325 (6): 393-397.
  7. Bell W. R., Braine H. G., Ness P. M., Kikler T. A. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N. Engl.J. Med. 1991; 325 (6): 398-403.
  8. George J. N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Blood 2000; 96 (4): 1223-1229.
  9. Bobbio-Pallavicini £., Gugliotta L., Centurioni R. et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP), results of a Randomised Multicenter Trial by the Italian Cooperative Group for TTP. Haematologica 1997; 82(4): 429-435.
  10. Dervenoulas /, Tsirigotis P., Bellas G. et al. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopenic purpura. A study of 44 cases. Acta Haematol. 2001; 105 (4): 204-208.
  11. Шустваль Н. Ф., Егоров В. П., Разладова Е. П., Аювджи Т. И. Случай тромботической тромбоцитопенической пурпуры. Клин. мед. 1986; 64 (11): 128-130.
  12. Теблоева Л. Т., Зверев Д. В., Цванг М. Б., Шумейко Н. К. Комплексная терапия тромботической тромбоцитопенической пурпуры. Педиатрия 1988; 67 (9): 46-48.
  13. Гладышев П. Л., Сидельман К. Н., Пестриков О. И., Григоричева Е. А. Случай болезни Мошкович. Клин. мед. 1989; 67(9): 113-115.
  14. Медведев П. В., Ливник А. В., Гласко Е. И., Прасолов Л. В. Описание случая тромботической тромбоцитопенической пурпуры. Пробл. гематол. 1998; 3: 46-49.
  15. Баркаган 3. С, Елыкомов В. А., Каминская В. М. и др. Опыт успешного применения криосупернатантной фракции плазмы в терапии крайне тяжелой формы тромботической тромбоцитопенической пурпуры. Гематол. и трансфузиол. 1999; 5: 22-24.
  16. Asada Y, Sumiyoshi A., Hayashi Т. et al. Immunohistochemis try of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb. Res. 1985; 38 (5): 469-479.
  17. Furlan M., Robles R., Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (1): 4223-4234.
  18. Tsai H.-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10): 4235-4244.
  19. Furlan M., Robles R., Galbucera M. et al. Von Willebrand factorcleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N. Engl. J. Med. 1998; 339(22): 1578-1584.
  20. Tsai H.-M., Lian E., Ch.-Y. Antibodies to von Willebrand factorcleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1998; 339 (22): 1585-1594.
  21. Gerritsen H. E., Robles R., Lammle В., Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98 (6): 1654-1661.
  22. Fujikawa K, Suzuki H., McMullen В., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (6): 1662-1666.
  23. Zheng X., Chung D., Takayama Т. К. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 2001; 276 (44): 41059-41063.
  24. Blanchi V., Robles R., Alberto L. et al. Von Willebrand factorcleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100 (2): 710-713.
  25. Studt J.-D., Kremer Hovinga A., Allberio L. et al. Von Wille brand factor-cleaving protease (ADAMTS-13) activity in thrombotic thrombocytopenic purpura: diagnostic experience 2001/2002 of a single research laboratory. Swiss. Med. Wkly 2003; 133 (23-24): 325-332.
  26. Tsai H.-M. Deficiency of ADAMTS13 and thrombotic throm- bocytopenic purpura. Blood 2002; 100 (10): 3839-3840.
  27. Lammle В., Bianchi V., Alberio L., Furlan M. ADAMTS13 and thrombotic thrombocytopenic purpura. Blood 2002; 100 (10): 3840-3841.
  28. Remuzzi G., Galbusera M.,Manucci P. M. ADAMTS13 in thrombotic microangiopathies. Blood 2002; 100 (10): 3842.
  29. Elliott M., Nichols W. Thrombotic thrombocytopenic purpura and hemolyticuremic syndrome. Mayo Clin. Proc. 2001; 76 (11): 1154-1162.
  30. Баркаган З. С. Геморрагические заболевания и синдромы. М.: Медицина; 1988.
  31. MunizA. E., Barbee R. W. Thrombotic thrombocytopenic purpura (TTP) presenting as pancreatitis. J. Emerg. Med. 2003; 24 (4): 407-411.
  32. Kathula S. K., Koduri J., Mall S., Chang J. С A case report of total abdominal hysterectomy resulting in acute thrombotic thrombocytopenic purpura with pancreatitis and hepatitis: complete resolution with plasma exchange therapy. Ther. Apher. Dial. 2003; 7 (3): 373-374.
  33. Ikhalaque N., Chang J. Thrombotic microangiopathy presenting as fulminanting rhabdomyolisis with multiorgan dysfunction. Hosp. Physician 2003; June: 51-56.
  34. Thompson С E., Damon L. E., Ries С A., Linker С. А. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992; 80 (8): 1890-1895.
  35. Meloni G., Proia A., Antonini G. et al. Thrombotic thrombocytopenic purpura: prospective neurologic, neuroimaging and neurophysiologic evaluation. Haematologica 2001; 86 (11): 1194-1199.
  36. Perelman S., Vilmer E., Bachelot C, Bourrillon A. Microangiopathic anaemia following thrombopenic purpura. Arch. Fr. Pediatr. 1993; 50 (8): 689-691.
  37. Milone J., Napal J., Bordone J. et al. Complete response in severe thrombotic microangiopathy post Bone Marrow Transplantation (BMT-TM) after multiple plasmaphereses. Bone Marrow Transplant. 1998; 22 (10): 1019-1021.
  38. Kanamori H., Takaishi Y, Takabayashi M. et al. Clinical significance of fragmented red cells after allogeneic bone marrow transplantation. Int. J. Hematol. 2003; 77 (2): 180-184.
  39. Burns E. R., Lou Y., Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am. J. Hematol. 2004; 75 (1): 18-21.
  40. George J. N., Vesely S. K. Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the community. Ann. Intern. Med. 2003; 138 (2): 152-153.
  41. Moake J. E. Thrombotic microangiopathies. N. Engl. J. Med. 2002; 347 (8): 589-600.
  42. Furlan M., Lammle B. Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura - new insights into underlying biochemical mechanisms. Nephrol. Dial. Transplant. 2000; 15 (8): 1112-1114.
  43. Tsai H.~M. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J. Mol. Med. 2002; 80 (10): 639-647.
  44. Myers L. Thrombotic thrombocytopenic purpura-haemolytic uraemic syndromes: pathophysiology and management. Nephrol. Nurs. J. 2002; 29 (2): 171-180.
  45. Proia A., Paesano R., Forcia F. et al. Thrombotic thrombocytopenic purpura and pregnancy: a case report and a review of the literature. Ann. Hematol. 2002; 81 (4): 210-214.
  46. Perez-Sanchez L, Anguita J., Pintado T. Use of cyclophospha- mide in treatment of thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: report of two cases. Ann. Hematol. 1999; 78 (6): 285-287.
  47. Gungor T, Furlan M., Lammle B. et al. Acquired deficiency of von Willebrand factor-cleaving protease patient suffering from acute systemic lupus erithematosus. Rheumatology 2001; 40 (8): 940-942.
  48. Yu T.-T., Fumg S. K.-Sh., Tsang W. K. et al. Refractory thrombotic thrombocytopenic purpura in a lupus nephritis patient. Hong Kong J. Nephrol. 2002; 4 (1): 51-53.
  49. Schattner A., Friedman J., Klepfish A. Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjogren's syndrome. Clin. Rheumatol. 2002; 21(1): 57-59.
  50. Bennett Ch. L., Davidson Ch. J., Raisch D. W. et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting coronary artery stents and stroke prevention. Arch. Intern. Med. 1999; 159 (21): 2524-2528.
  51. Steinbubl St. R., Tan W. A., Foody J. M. et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. J. A. M. A. 1999; 281 (9): 806-810.
  52. Tsai H.-M., Rice L., Sarode R. et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann. Intern. Med. 2000; 132 (10): 794-799.
  53. Bennett Ch. L., Connors J. M., Carwile J. M. et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N.Engl. J. Med. 2000; 342 (24): 1773-1777.
  54. Zakarija A., Bandarenko N., Pandey D. K. et al. Clopidogrelassociated Thrombotic Thrombocytopenic Purpura (TTP): clinical characteristics and predictors of survival. Blood 2003; 102(11): abstr. 1977.
  55. Kojouri K., Vesely S., George G. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann. Intern. Med. 2001; 135 (12): 1047-1051.
  56. Chemnitz J. M., Schulz A., Salameh A. et al. Thrombotic thrombocytopenic purpura (Moschkowitz-Syndrome) caused by ticlopidine. Med. Klin. 2000; 95 (2): 96-100.
  57. Elliott M. A., Nichols W. L., Plumnoff E. A. et al. Posttransplantation thrombotic thrombocytopenic purpura: a Single- Center experience and a contemporary review. Mayo Clin. Proc. 2003; 78 (4): 421-430.
  58. Ruutu Т., Hermans J., Niederwieser D. et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br. J. Haematol. 2002; 118 (4): 1112-1129.
  59. Knobl P., Rintelen P., Komek G. et al. Plasma exchange for treatment of thrombotic thrombocytopenic purpura in critically ill patients. Intensive Care Med. 1997; 23 (1): 44-50.
  60. Zeigler Z. R., Shadduck R. K., Nemunaitis J. et al. Bone marrows transplant-associated thrombotic thrombocytopenic purpura: a case series. Bone Marrow Transplant. 1995; 15 (2): 247-253.
  61. Dunlas St., Todd Т. A., Stewart Al. I. et al. The Central Scotland Escherichia coli 0157:H7 Outbreak: risk factors for the hemolitic uremic syndrome and death among hospitalized patients. Clin. Infect. Dis. 2001; 33 (7): 923-931.
  62. eiMhmed S., Siddiqui R. K., Siddiqui S. A. et al. HIV associated thrombotic microangiopathy. Postgrad. Med. J. 2002; 78 (923): 520-525.
  63. Volberding P. A., Baker K. R., Levine A. M. Human immunodeficiency virus in hematology. Hematology 2003. 294-313.
  64. Mash C, Peraldi M. N., Descenclos J. C. et al. Thrombotic microangiopathy and cytomegalovirus disease in patients in- fected with human immunodeficiency virus. Clin. Infect. Dis. 1997; 24 (3): 350-355.
  65. Gonzalez N.. Rios £,. Martin-Noya A., Rodriguez J- M. TTP and bone marrow necrosis as a complication of gastric neoplasm. Haematologica 2002; 87 (1): ECR01.
  66. Chang J. C, Naqvi T. Thrombotic thrombocytopenic Purpura associated with bone marrow metastatic and secondary mielofibrosis in cancer. Oncologist 2003; 8 (4): 375-380.
  67. Roy V., Rizvi M. A., Vesely S. K., George G. N. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrows Transplant. 2001; 27 (6): 641-646.
  68. Coppo P., Busel A., Charrier S. et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Medicine (Baltimore) 2003; 82 (1): 27-38.
  69. Sgarabotto D., Vianello F., Scano F. et al. Clinical and laboratoristic remission after cryosupernatant plasma exchange in thrombotic thrombocytopenic purpura. Haematologica 1998; 83 (6): 569-570.
  70. Bobbio-Pallavicini E., Porta C, Centurioni R. et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic pur pura refractory to plasma-exchange. The Italian Cooperative Group for TTP. Eur. J. Haematol. 1994; 52 (4): 222-226.
  71. Ferrara F., Copia C, Annunziata M. et al. Vincristine as salvage treatment for refractory thrombotic tghrombocytopenic purpura. Ann. Hematoi. 1999; 78 (11): 521-523.
  72. Allan D. S., Kovacs M. J., Clark W. F. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001; 86 (8): 844-850.
  73. Chemnitz J-, Draube A., Scheid С et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am. J. Hematoi. 2002; 71 (2): 105-108.
  74. Gutterman L. A., Kloster В., Tsai H.-M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol. Dis. 2002; 28 (3): 385-391.
  75. Tsai H.-M., Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur. J. Haematol. 2003; 70 (3): 183-185.
  76. Zheng X., Pallera A. M., Goodnough L. T. et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann. Inern. Med. 2003; 138 (2): 105-108.
  77. Spiekermann K., Wormann A, Rumpf K. W., Hiddemann W. Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura. Br. J. Haematol. 1997: 97 (3): 544-546.
  78. Musso M., Porretto F, Crescimanno A. et al. Successful treatment of resistant thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome with autologous peripheral blood stem and progenitor (CD34") cell transplantation. Bone Mar row Transplant. 1999; 24 (2): 207-209.
  79. Aqui N. A., Stein S. H., Konkle B. A. et al. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J. Clin. Apheres. 2003; 18 (2): 51-54.
  80. Gervasoni C, Ridolfo A. L., Vaccarezza M. et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin. Infect. Dis. 2002; 35 (12): 1534-1540.
  81. Baldunini С Thrombotic thrombocytopenic purpura: now is the time for clinical trials. Haematology 2000; 85 (4): 337- 338
  82. George J. N, Vesely S. K., Terrell D. R. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin. Hematoi. 2004; 41 (1): 60-67.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies